$SILO

Silo Pharma, Inc. (SILO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 18, 2026, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Parkview Consulting LLC (the “Seller”). Pursuant to the Agreement, the Seller agreed to sell, and the Compan

Silo Pharma, Inc. (SILO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On August 14, 2026, shareholders of Silo Pharma, Inc. (the “Company”) approved an increase to the number of authorized shares of the Company’s common stock, par value $0.0001 (“Common Stock”) from

Indonesia Stock Exchange (IDX) expanded its High Shareholding Concentration (HSC) list to 51 stocks, adding names including DCII, BYAN, and MORA. The HSC label highlights concentrated ownership and potential liquidity and price sensitivity risks. IDX cited updated methodology and noted regulators are assessing liquidity quality ahead of MSCI review in Nov 2026.

Silo Pharma (Nasdaq: SILO) said its wholly owned subsidiary QwikAgents was accepted into AMD’s AI Developer Program, gaining access to AMD Developer Cloud credits, tools, and training resources. QwikAgents is developing an enterprise AI agent platform with starter plans from $14 per month, targeting deployment, testing, optimization, benchmarking, and potential training of agent workloads.

Silo Pharma, Inc. (SILO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 ea029760202ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 9, 2026, between Silo Pharma, Inc., a Nevada corporation (the “ Company ”), and each purcha

Silo Pharma (NASDAQ: SILO) said it entered definitive agreements for a private placement at-the-market under NASDAQ rules to issue and sell 619,965 shares, or pre-funded warrants, plus Series A-3 and short-term Series A-4 warrants. Price was $6.452 per share, with $6.21 exercise price. Gross proceeds are about $4 million, up to $7.7 million if warrants are fully exercised.

Silo Pharma (Nasdaq: SILO) announced a private placement under Nasdaq at-the-market rules to issue 619,965 shares (or pre-funded warrants) at $6.452 per share, with Series A-3 and short-term Series A-4 warrants exercisable immediately. Gross proceeds are expected at about $4.0M, with up to about $7.7M more if warrants are fully exercised. Proceeds will fund working capital and general corporate purposes.

U.S. stock index futures were mixed premarket on Friday, with S&P 500 futures flat and Nasdaq 100 futures down 0.3% by 08:25 ET. CCC Intelligent Solutions rose 14.5% on a Reuters report it is exploring a sale with Morgan Stanley. Circle gained 7% after OCC approval for a digital currency bank. Meta rose 3.8% on a new AI model. Fermi America fell 14.6% after pricing $375m convertible notes, and Silo Pharma dropped 22% on an up to $11.7m ATM placement.

Silo Pharma (NASDAQ:SILO) shares dropped 22% after the company announced an up to $11.7 million private placement under Nasdaq rules. It plans to issue 619,965 shares plus Series A-3 and A-4 warrants for up to 619,965 shares each at $6.452 per share. Expected gross proceeds are about $4 million upfront, with up to about $7.7 million more if warrants are exercised.

Certara said it is integrating Nvidia’s BioNeMo Agent Toolkit into its AI drug development platform, adding agentic frameworks to support tasks across dosing optimization, clinical-data analysis, ADMET evaluation and regulatory evidence. Silo Pharma’s subsidiary QwikAgents joined Nvidia’s Developer Program to expand its autonomous AI agent platform. NVDA shares were up; Certara and Silo were down at publication.